Replimune Group, Inc. - 8-K Filing
Replimune Group announced that the FDA has accepted for review its resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab to treat advanced melanoma. The FDA set an action date of August 2, 2026, and plans to hold an advisory committee meeting in late July. (Items: 7.01 of this Current Report on Form 8-K, including Exhibit 99)
Tickers: $REPL